Diabetes Drug

Hetero plans to launch the drug in India in ‌April, focusing on building market share overseas to begin with, Managing Director Vamsi Krishna Bandi said

Researchers say metformin may mimic some exercise benefits in prostate cancer patients, helping manage metabolism and fatigue, though it cannot replace physical activity

What feels like simple tiredness could signal heat exhaustion, and recognising early symptoms can help prevent serious complications and life-threatening heatstroke during extreme summer conditions

To prevent unauthorised sale, unsupervised use, and other malpractices, the Drug Controller of India has intensified its regulatory surveillance, warning that the drugs can lead to serious side effect

Findings show metformin acts on the brain at low doses, reshaping decades of understanding and pointing to more targeted approaches in diabetes treatment

Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in

Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market

Zydus Lifesciences on Wednesday has received approval from the US health regulator to market a generic diabetes drug in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Dapagliflozin Tablets in strengths of 5 mg and 10 mg, the drug firm said in a statement. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. The company said the tablets will be manufactured at its formulation manufacturing facility at SEZ, Ahmedabad. As per the industry estimates, Dapagliflozin tablets had annual sales of USD 10,486.9 million in the US. Zydus shares on Wednesday ended 0.23 per cent up at Rs 905 apiece on BSE.

Ozempic, a once-weekly injectable approved by the US Food and Drug Administration in 2017 for type 2 diabetes, has become a global bestseller and is widely used off-label for weight los

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

WHO adds GLP-1 drugs for type 2 diabetes to its Essential Medicines List, as Indian pharma firms prepare to launch generics amid surging demand and patent expirations

Government may fix retail prices for empagliflozin combinations as generic versions flood the market following the drug's patent expiry, causing price drops

Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication. The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with ...

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

India gets yet another diabetes and obesity management drug- a popular competitor of Ozempic that has been available in India. Watch the video to know the details.

The uptick in the Morepen Labs share came after the company announced that it has rolled out 'Empamore.'

Mankind, Alkem, Glenmark launch generic versions of empagliflozin